Residency · Residency · Otolaryngology

Chronic Rhinosinusitis with Nasal Polyps and Biologics

Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a distinct inflammatory phenotype driven predominantly by type 2 inflammation. Despite surgical and traditional medical management, recurrence rates are high. The advent of biologic therapies targeting specific inflammatory pathways has transformed the treatment paradigm, though controversies around patient selection, cost-effectiveness, and integration with surgery remain active areas of debate.

Pathophysiology of Type 2 Inflammation

CRSwNP is predominantly a type 2 (Th2) inflammatory process. Key cytokines: IL-4, IL-5, IL-13. IL-4 and IL-13: drive IgE class switching, goblet cell hyperplasia, and barrier dysfunction. IL-5: promotes eosinophil maturation, recruitment, and survival. Tissue eosinophilia is the hallmark histologic finding. Epithelial-derived alarmins (TSLP, IL-25, IL-33) initiate the type 2 cascade by activating innate lymphoid cells type 2 (ILC2s). Elevated tissue and serum IgE, periostin, and eosinophil cationic protein. Staphylococcal superantigens may amplify the local IgE response. Fibrin deposition and edema lead to polyp formation.

Associated Conditions

Asthma: present in 40-70% of CRSwNP patients; more severe asthma with more severe polyps. Aspirin-exacerbated respiratory disease (AERD / Samter triad): CRSwNP + asthma + aspirin/NSAID sensitivity; driven by leukotriene overproduction; particularly aggressive polyp recurrence. Allergic fungal rhinosinusitis (AFRS): overlap with CRSwNP; discussed in Topic 15. Cystic fibrosis: nasal polyps in children should raise suspicion.

Clinical Presentation

Nasal obstruction (bilateral, progressive), Anosmia/hyposmia (often the most bothersome symptom), Rhinorrhea (anterior and posterior nasal drainage), Facial pressure. Nasal endoscopy: bilateral translucent, edematous polyps emanating from the middle meatus. Polyps typically bilateral; unilateral polyps require biopsy to exclude neoplasm.

Diagnosis and Workup

Nasal endoscopy with polyp grading. CT sinus: diffuse ethmoid-predominant opacification; peripheral hyperattenuation in AERD. Lund-Mackay score for disease extent. Serum biomarkers: total IgE, blood eosinophil count, periostin. Tissue eosinophils on biopsy (>10 per HPF suggests type 2 endotype). Aspirin challenge if AERD suspected, Allergy testing. Consider cystic fibrosis workup in young patients with polyps.

Traditional Medical Management

Intranasal corticosteroids: foundation of therapy; daily long-term use. Topical steroid irrigations: budesonide 0.5 mg in 240 mL saline; evidence for benefit in CRSwNP. Short-course oral corticosteroids: prednisone 0.5-1 mg/kg for 5-14 days; rapid symptom relief but temporary; limit courses due to cumulative side effects. Saline irrigation: high-volume daily. Leukotriene modifiers: montelukast; modest benefit, particularly in AERD. Aspirin desensitization: for AERD; daily aspirin 325-650 mg after graded challenge; reduces polyp recurrence and need for revision surgery. Macrolide therapy: limited role in CRSwNP (more effective in CRSsNP with low IgE). Doxycycline: 200 mg day 1, then 100 mg daily for 20 days; may reduce polyp size via anti-inflammatory and anti-matrix metalloproteinase effects.

Biologic Therapies

Dupilumab (Dupixent) -- FDA-approved for CRSwNP

Target: IL-4 receptor alpha subunit; blocks both IL-4 and IL-13 signaling. Dosing: 300 mg subcutaneous every 2 weeks. Evidence: LIBERTY NP SINUS-24 and SINUS-52 trials. Significant reduction in nasal polyp score (NPS), Lund-Mackay CT score, and SNOT-22 symptom score. Improvement in olfaction. Reduced need for oral steroids and surgery. Also approved for: atopic dermatitis, moderate-severe asthma (type 2), eosinophilic esophagitis. Side effects: injection site reactions, conjunctivitis, eosinophilia (transient).

Omalizumab (Xolair) -- FDA-approved for CRSwNP

Target: IgE (anti-IgE monoclonal antibody). Dosing: based on serum IgE and body weight; subcutaneous every 2-4 weeks. Evidence: POLYP 1 and POLYP 2 trials. Significant NPS reduction and symptom improvement. Benefit greatest in patients with elevated IgE and comorbid asthma. Also approved for: allergic asthma, chronic urticaria. Side effects: injection site reactions, anaphylaxis risk (0.1-0.2%), arthralgia.

Mepolizumab (Nucala) -- FDA-approved for CRSwNP

Target: IL-5 (anti-IL-5 monoclonal antibody). Dosing: 100 mg subcutaneous every 4 weeks. Evidence: SYNAPSE trial. Reduction in NPS and need for surgery. Improvement in nasal obstruction VAS score. Also approved for: severe eosinophilic asthma, EGPA. Side effects: injection site reactions, headache.

Benralizumab (Fasenra)

Target: IL-5 receptor alpha; depletes eosinophils via ADCC. Evidence: OSTRO trial showed NPS reduction; FDA approval for CRSwNP in 2024. Dosing: 30 mg subcutaneous every 4 weeks for 3 doses, then every 8 weeks. Near-complete eosinophil depletion.

Emerging Biologics

Tezepelumab (anti-TSLP): targets upstream alarmin; trials in CRSwNP ongoing. Itepekimab (anti-IL-33): trials in progress. Biologics targeting multiple pathways in development.

Patient Selection for Biologics [CONTROVERSY]

Generally considered for moderate-to-severe CRSwNP after failure of medical therapy with or without prior surgery. Proposed criteria (EPOS 2020): at least 3 of the following despite surgery and appropriate medical therapy: Type 2 inflammation (tissue eosinophils >10/HPF or blood eosinophils >250 cells/mcL). Need for systemic corticosteroids (>2 courses/year). Significantly impaired quality of life (SNOT-22 >40). Significant loss of smell. Comorbid asthma requiring regular inhaled corticosteroids. Cost: $30,000-40,000/year; cost-effectiveness debated. Duration of therapy: unclear; symptoms recur after discontinuation; likely long-term or indefinite.

Surgery vs. Biologics vs. Combined Approach [CONTROVERSY]

FESS remains the standard intervention after medical therapy failure. Biologics may delay or reduce need for surgery. Combined approach (surgery + biologic): may provide best outcomes by reducing polyp recurrence post-FESS. No head-to-head trials comparing surgery vs. biologics as first intervention after medical therapy failure. Shared decision-making based on disease severity, patient preference, access, and cost. Surgery provides immediate benefit; biologics require ongoing use.

Monitoring Response to Biologics

Nasal polyp score (endoscopic grading): primary endpoint. SNOT-22 symptom score: patient-reported outcomes. Olfaction testing (UPSIT, Sniffin' Sticks). Blood eosinophils, serum IgE (may not correlate directly with clinical response). CT sinus (Lund-Mackay) if considering surgery. Reassess at 16-24 weeks; consider switch to alternative biologic if inadequate response.

<image>Diagram of the type 2 inflammatory cascade in CRSwNP. Starting at the nasal epithelium with allergens, pollutants, and Staphylococcus aureus superantigens triggering release of epithelial alarmins (TSLP, IL-25, IL-33). These activate ILC2 cells and dendritic cells, leading to Th2 cell differentiation. Th2 cells and ILC2s produce IL-4, IL-5, and IL-13. Downstream effects shown: IL-5 driving eosinophil recruitment and activation, IL-4/IL-13 driving B cell IgE class switching and goblet cell hyperplasia, tissue edema, and polyp formation. Biologic targets are indicated at each intervention point: dupilumab (IL-4Ralpha), omalizumab (IgE), mepolizumab (IL-5), benralizumab (IL-5R), tezepelumab (TSLP).</image>

<image>Endoscopic photographs comparing CRSwNP before and after biologic therapy. Left panel: bilateral nasal polyps (grade 3) completely filling the nasal cavity, obscuring the middle turbinate and septum. Right panel: same patient after 6 months of dupilumab therapy showing dramatically reduced polyp burden, visible middle turbinates, and patent nasal airway. Polyp grading scale (0-3) shown in an inset diagram.</image>

<image>Treatment algorithm for CRSwNP management integrating biologics. Flowchart starting with diagnosis and initial medical therapy (intranasal steroids, saline, short-course oral steroids), then branching based on response. For inadequate response: assess type 2 biomarkers. If positive: consider biologics or FESS. Decision points for surgery alone, biologics alone, or combined surgery plus biologic maintenance therapy. Reassessment timepoints and criteria for switching biologic agents are indicated.</image>

Clinical Pearls

CRSwNP is fundamentally a medical disease with surgical adjuncts; patients require lifelong management regardless of treatment approach. Unilateral nasal polyps are not typical CRSwNP and should be biopsied to exclude inverted papilloma, antrochoanal polyp, or malignancy. Anosmia is often the most impactful symptom for patients and one of the most responsive to biologic therapy. AERD patients have the most aggressive polyp recurrence and may benefit most from aspirin desensitization or biologic therapy. Biologics are not curative; symptoms return after discontinuation, necessitating long-term commitment. Cost is the major barrier to biologic access; insurance approval typically requires documentation of failed medical and surgical therapy. Blood eosinophil count and total IgE are imperfect predictors of biologic response; tissue eosinophilia is more informative. Dupilumab is often considered first-line biologic for CRSwNP due to the broadest evidence base and dual IL-4/IL-13 blockade.

References

• Bachert C, Han JK, Desrosiers M, et al. "Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and SINUS-52)." Lancet. 2019;394(10209):1638-1650.
• Gevaert P, Omachi TA, Corren J, et al. "Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials (POLYP 1 and POLYP 2)." J Allergy Clin Immunol. 2020;146(3):595-605.
• Han JK, Bachert C, Fokkens W, et al. "Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE)." Lancet Respir Med. 2021;9(10):1141-1153.
• Fokkens WJ, Lund VJ, Hopkins C, et al. "EPOS 2020." Rhinology. 2020;58(Suppl S29):1-464.

Read this lecture as Markdown